Real-Time Oncology Review Speeds Supplements At US FDA, But Gives Modest Benefit For Novel Agents

US FDA’s 72 approvals under streamlined submission program consistently come before the PDUFA goal date, Pink Sheet analysis shows, but benefit ranges from 2 weeks for priority review novel agents to 1.8 months for other priority applications.